{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T22:33:12Z","timestamp":1786660392274,"version":"build-2736575974"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,21]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Diffuse large B-cell lymphoma (DLBCL) is a common subtype of non-Hodgkin\u2019s lymphoma characterized by high malignancy, rapid onset and aggressive clinical behavior. The disease exhibits considerable heterogeneity, which influences clinical and immunophenotypic characteristics, which in turn affect treatment outcomes and prognosis. Recently, targeted therapies have been introduced, offering improved therapeutic efficacy but with risks such as immunosuppression and opportunistic infections.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>We report a case of a patient diagnosed with DLBCL who experienced immunosuppression as a result of treatment with rituximab and a Bruton\u2019s tyrosine kinase inhibitor, which subsequently led to Strongyloides stercoralis infection.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>The patient was diagnosed with S. stercoralis infection, confirmed by appropriate diagnostic tests after the onset of clinical symptoms suggestive of parasitic infection.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient was treated with a combination of rituximab and a Bruton\u2019s tyrosine kinase inhibitor as part of her DLBCL therapy. Antiparasitic treatment was started after diagnosis of S. stercoralis infection.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient\u2019s infection was successfully managed with antiparasitic therapy, although the case highlights the need for vigilant monitoring of immunosuppressive therapy in patients with DLBCL due to the risk of opportunistic infections.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>This case highlights the potential complications of targeted therapies in DLBCL, particularly the risk of opportunistic infections such as S. stercoralis. It highlights the importance of careful patient monitoring and prompt intervention to effectively manage such infections.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000041533","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T15:02:46Z","timestamp":1740409366000},"page":"e41533","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Strongyloides stercoralis infection in a DLBCL patient treated with rituximab and BTK inhibitor: A case report and literature review"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3078-1631","authenticated-orcid":false,"given":"Wanyi","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital, Fujian Medical University, Quanzhou, Fujian Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zechuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital, Fujian Medical University, Quanzhou, Fujian Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqiang","family":"Wu","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian Province, China"},{"name":"The Second Clinical Medical College, Fujian Medical University, Fujian, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital, Fujian Medical University, Quanzhou, Fujian Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital, Fujian Medical University, Quanzhou, Fujian Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihuang","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital, Fujian Medical University, Quanzhou, Fujian Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6976-6039","authenticated-orcid":false,"given":"Jianxin","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital, Fujian Medical University, Quanzhou, Fujian Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250805","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma.","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med"},{"key":"R2-20250805","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"key":"R3-20250805","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41408-021-00456-w","article-title":"Diffuse large B-cell lymphoma: new targets and novel therapies.","volume":"11","author":"Cheson","year":"2021","journal-title":"Blood Cancer J"},{"key":"R4-20250805","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1182\/bloodadvances.2020001685","article-title":"Targeting phosphatidylinositol 3 kinase-\u03b2 and -\u03b4 for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma.","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"key":"R5-20250805","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.mayocp.2023.05.017","article-title":"Invasive central nervous system aspergillosis in a patient receiving long-term acalabrutinib therapy.","volume":"98","author":"Tawfiq","year":"2023","journal-title":"Mayo Clin Proc"},{"key":"R6-20250805","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1182\/blood-2018-02-832154","article-title":"Ibrutinib and fungus: an invasive concern.","volume":"131","author":"Rogers","year":"2018","journal-title":"Blood"},{"key":"R7-20250805","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity.","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"key":"R8-20250805","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton\u2019s tyrosine kinase in B cells and malignancies.","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol Cancer"},{"key":"R9-20250805","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"R10-20250805","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.ccell.2021.10.006","article-title":"Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL.","volume":"39","author":"Wilson","year":"2021","journal-title":"Cancer Cell"},{"key":"R11-20250805","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1158\/1078-0432.CCR-24-0605","article-title":"A phase II study assessing long-term response to ibrutinib monotherapy in recurrent or refractory CNS lymphoma.","volume":"30","author":"Grommes","year":"2024","journal-title":"Clin Cancer Res"},{"key":"R12-20250805","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1200\/JCO.20.01594","article-title":"Next-generation Bruton tyrosine kinase inhibitors.","volume":"38","author":"Stephens","year":"2020","journal-title":"J Clin Oncol"},{"key":"R13-20250805","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma.","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell"},{"key":"R14-20250805","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.idc.2018.10.006","article-title":"Strongyloidiasis: a neglected tropical disease.","volume":"33","author":"Krolewiecki","year":"2019","journal-title":"Infect Dis Clin North Am"},{"key":"R15-20250805","doi-asserted-by":"crossref","first-page":"100227","DOI":"10.1016\/j.clinme.2024.100227","article-title":"Strongyloides stercoralis infection in the UK: a systematic review and meta-analysis of published cases.","volume":"24","author":"Alam","year":"2024","journal-title":"Clin Med (Lond)"},{"key":"R16-20250805","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00408-022-00528-z","article-title":"Strongyloides stercoralis.","volume":"200","author":"Czeresnia","year":"2022","journal-title":"Lung"},{"key":"R17-20250805","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1128\/CMR.17.1.208-217.2004","article-title":"Strongyloides stercoralis in the immunocompromised population.","volume":"17","author":"Keiser","year":"2004","journal-title":"Clin Microbiol Rev"},{"key":"R18-20250805","first-page":"549","article-title":"Acute lymphoblastic leukemia with eosinophilia and Strongyloides stercoralis hyperinfection.","volume":"21","author":"Nesheli","year":"2011","journal-title":"Iran J Pediatr"},{"key":"R19-20250805","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/cncr.20120","article-title":"Strongyloidiasis in patients at a comprehensive cancer center in the United States.","volume":"100","author":"Safdar","year":"2004","journal-title":"Cancer"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041533","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T17:23:20Z","timestamp":1754414600000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000041533","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]}}}